Skip to main content

Advertisement

Table 1 Patients’ characteristics according to receptor stable and any receptor conversion

From: Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy

Characteristics All patients Receptor stable Any receptor conversion P
(N = 231) (N = 176) (N = 55)
Age, years
 ≤ 50 158 (68.4) 113 (64.2) 45 (81.8) 0.014
 > 50 73 (31.6) 63 (35.8) 10 (18.2)
Initial tumor stage
 T1 41 (17.7) 34 (19.3) 7 (12.7) 0.500
 T2 119 (51.5) 90 (51.1) 29 (52.7)  
 T3 or T4 71 (30.7) 52 (29.5) 19 (34.5)  
Initial node status
 Negative 32 (13.9) 22 (12.5) 10 (18.2) 0.287
 Positive 199 (86.1) 154 (87.5) 45 (81.8)
Nuclear grade
 1 or 2 74 (32.0) 60 (56.6) 14 (46.7) 0.335
 3 62 (26.8) 46 (43.4) 16 (53.3)
 NA 95 (41.1)
Histology
 IDC 201 (87.0) 154 (87.5) 47 (85.5) 0.832
 Mixed 17 (7.4) 13 (7.4) 4 (7.3)
 Other 13 (5.6) 9 (5.1) 4 (7.3)
Initial ER status
 Negative 10 (4.3) 3 (1.7) 7 (12.7) < 0.001
 Positive 221 (95.7) 173 (98.3) 48 (87.3)
Initial PR status
 Negative 31 (13.4) 18 (10.2) 13 (23.6) 0.011
 Positive 200 (86.6) 158 (89.8) 42 (76.4)
Initial HER2 status
 Negative 194 (84.0) 150 (85.2) 44 (80.0) 0.356
 Positive 37 (16.0) 26 (14.8) 11 (20.0)  
Initial Ki-67 status
 < 15% 59 (25.5) 48 (27.3) 11 (20.0) 0.280
 ≥ 15% 172 (74.5) 128 (72.7) 44 (80.0)
NAC cycles
 1–4 153 (66.2) 117 (66.5) 36 (65.5) 0.889
 5–8 78 (33.8) 59 (33.5) 19 (34.5)
NAC regimens
 Anthracycline-based 71 (30.7) 53 (30.1) 18 (32.7) 0.879
 Anthracycline- and taxane-based 140 (60.6) 107 (60.8) 33 (60.0)
 Taxane-based 20 (8.7) 16 (9.1) 4 (7.3)
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy